| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Finch Therapeutics Group, Inc. (FNCH) has 0 insiders with recent SEC Form 4 filings, including 5 buys and 6 sells. FNCH is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 28, 2024 | Smisek Jeffery A | Director | Sell | 8,242 | $2.58 | $21,245.94 | -55.9% | -48.1% | +440.6% | |
| Nov 22, 2023 | Smisek Jeffery A | Director | Sell | 1,470 | $3.64 | $5,350.80 | -18.1% | -32.4% | +209.5% | |
| Jun 9, 2023 | Graf Susan E | Director | Buy | 5,010 | $0.27 | $1,352.70 | New | -23.4% | -83.6% | |
| Feb 21, 2023 | Blaustein Marc | Chief Operating Officer | Sell | 4,619 | $0.38 | $1,755.22 | -14.2% | -25.0% | -78.3% | |
| Oct 21, 2022 | Blaustein Marc | Chief Operating Officer | Sell | 3,636 | $1.39 | $5,054.04 | -10.0% | -61.6% | -90.1% | |
| Oct 21, 2022 | Vittiglio Joseph | Chief Business &Legal Officer | Sell | 3,636 | $1.39 | $5,054.04 | -10.4% | -61.6% | -90.1% | |
| Dec 20, 2021 | Haft Nicholas | Director | Buy | 63,850 | $10.18 | $649,993.00 | +1.6% | -44.6% | -94.0% | |
| Mar 23, 2021 | Smisek Jeffery A | Director | Buy | 88,235 | $17.00 | $1,499,995.00 | +5.5% | - | - | |
| Mar 23, 2021 | Haft Nicholas | Director | Buy | 882,351 | $17.00 | $14,999,967.00 | New | - | - | |
| Mar 23, 2021 | Crestovo Investor LLC | Director, 10% Owner | Buy | 735,294 | $17.00 | $12,499,998.00 | +6.2% | - | - |